Diagnostic Enzymes by Applications

Lipid-related assays use coordinated enzyme reactions to measure total cholesterol, triglycerides, non-esterified fatty acids (NEFA), lipoprotein-associated cholesterol, and total bile acids. Representative components include cholesterol esterase, cholesterol oxidase, lipase, glycerol kinase, glycerol-3-phosphate oxidase, acyl-CoA synthetase, acyl-CoA oxidase, 3α-hydroxysteroid dehydrogenase, and peroxide-reporting enzymes.

This category supports applications involving:

• Total cholesterol, triglyceride, NEFA, HDL-C, LDL-C, and total bile acid methods.
• Hydrolysis, activation, oxidation, cofactor-cycling, and peroxide-reporting reactions.
• Evaluation of substrate coverage, lipemic samples, reagent blank, calibration, and cascade balance.

Clinical chemistry encompasses concentration assays for metabolites and substrates as well as catalytic-activity assays in which the enzyme present in the specimen is itself the measurand. Oxidases, dehydrogenases, hydrolases, transferases, and auxiliary enzymes may be combined in endpoint, fixed-time, or kinetic methods for serum, plasma, urine, whole blood, or other validated matrices.

The collection is relevant to:

• Metabolite assays such as glucose, lactate, uric acid, creatinine, cholesterol, and triglycerides.
• Activity assays for clinically relevant enzymes using substrates, cofactors, and coupling systems.
• Automated analyzer, microplate, liquid-reagent, dry-chemistry, and research workflows.

Glucose testing may use glucose oxidase, hexokinase with glucose-6-phosphate dehydrogenase, or a glucose dehydrogenase system. These routes differ in oxygen dependence, cofactor requirement, substrate specificity, signal generation, and compatibility with laboratory analyzers or electrochemical sensors. Related metabolic assays may require additional enzymes for glycated-protein, ketone, or other diabetes-associated measurements.

Product selection should account for:

• The difference between glucose oxidase, nicotinamide-dependent GDH, FAD-GDH, PQQ-GDH, and hexokinase systems.
• Cross-reactivity, oxygen effects, mediator or cofactor chemistry, specimen matrix, and hematocrit where relevant.
• Stability in liquid reagents, dry test strips, cartridges, and other point-of-care configurations.

Enzyme-based renal function testing commonly includes creatinine, uric acid, and urea-related methods. Creatinine can be measured through a creatininase–creatinase–sarcosine oxidase cascade, urate through uricase-dependent peroxide generation, and urea through urease followed by a compatible detection reaction. Each method requires its own calibration, interference assessment, and specimen-handling controls.

This category helps developers identify:

• Primary and auxiliary enzymes for renal chemistry assays.
• Products for colorimetric, ultraviolet, kinetic, and compatible biosensor methods.
• Options for managing endogenous intermediates, reducing substances, matrix effects, and multienzyme balance.

Pancreatic testing may measure the catalytic activity or concentration of enzymes released by the pancreas, including α-amylase, pancreatic lipase, trypsin-related targets, and pancreatic elastase. In these applications, the pancreatic enzyme can be the analyte rather than a reagent. Auxiliary enzymes, defined substrates, reporter systems, reference preparations, and immunoassay reagents may be required to convert that analyte into a quantitative result.

Relevant development questions include:

• Whether the method measures total enzyme activity, a pancreatic isoform, or antigen concentration.
• Substrate specificity, auxiliary-enzyme excess, reaction timing, and traceability of activity values.
• Suitability of the product as an active standard, control component, antigen, or reagent enzyme.

Liver panels combine different types of measurands. ALT, AST, ALP, GGT, and sometimes LDH are measured as catalytic activities, whereas bile acids, bilirubin, ammonia, and other metabolites require separate chemical, enzymatic, or immunochemical methods. A reagent enzyme, auxiliary enzyme, or active enzyme reference must therefore be chosen according to its analytical role.

The category includes products relevant to:

• Aminotransferase, phosphatase, transferase, and dehydrogenase activity methods.
• Total bile acid, ammonia, and related metabolite reaction systems.
• Calibrator or control development, coupled reactions, and kinetic analyzer applications.

Point-of-care and biosensor platforms integrate a biological recognition reaction with a compact signal transducer. Oxidases and dehydrogenases are widely used for glucose, lactate, urate, cholesterol-related, and other small-molecule sensors. Performance depends on more than catalytic activity: immobilization, mediator chemistry, oxygen transport, membrane selectivity, electrode potential, temperature, humidity, and dry-state storage can all affect the result.

This application area addresses:

• Enzyme recognition layers for electrochemical, optical, and colorimetric devices.
• Immobilization, mediator compatibility, response time, operational stability, and interference control.
• Dry strips, disposable cartridges, wearable concepts, and other miniaturized analytical formats.

Cardiac and skeletal muscle injury testing may involve catalytic activity assays, isoenzyme measurements, or immunoassays for structural proteins. Creatine kinase and lactate dehydrogenase can serve as analytes or reference materials, while hexokinase, glucose-6-phosphate dehydrogenase, pyruvate kinase, and reporter enzymes may support coupled detection. Cardiac troponins are proteins rather than enzymes and are detected mainly by immunoassay.

The product collection supports:

• Total CK, CK isoenzyme, LDH, aldolase, and related activity-assay development.
• Active standards, isoenzyme preparations, controls, coupling enzymes, and enzyme reporters.
• Clear differentiation among activity measurement, mass immunoassay, and secondary signal generation.

Many electrolytes are routinely measured by ion-selective electrodes or nonenzymatic chemistry, but enzyme-coupled methods can be useful for selected ions and small metabolites. Examples include urease-dependent urea methods, glutamate dehydrogenase-based ammonia detection, dehydrogenase assays for alcohols or organic acids, and enzyme systems whose activity changes in response to a required ion or inhibitor.

Selection requires attention to:

• Whether the ion or metabolite is converted directly, measured through a coupled reaction, or inferred from enzyme modulation.
• Cofactor, substrate, ionic-strength, pH, and matrix requirements.
• Selectivity against related ions or metabolites and comparison with the intended reference or routine method.

Environmental enzyme assays can support the detection or screening of phenolic compounds, organophosphate or carbamate pesticides, nutrients, oxidants, and other contaminants. Laccases, peroxidases, phosphatases, cholinesterases, dehydrogenases, and related enzymes may be used as recognition or indicator components. In inhibition-based assays, a response can indicate the presence of an inhibitor but does not automatically identify a specific contaminant.

Environmental method development should consider:

• Water, soil extract, sediment, wastewater, or other explicitly validated matrices.
• Cross-reactivity, enzyme inhibition, turbidity, colored matter, salinity, pH, and sample pretreatment.
• Whether the method is intended for screening, monitoring, quantification, or confirmatory analysis.

Food testing uses enzymes in several distinct ways: to release an analyte during sample preparation, convert a food component into a measurable signal, amplify pathogen nucleic acids, or generate an immunoassay readout. Relevant targets may include sugars, organic acids, alcohols, allergens, microbial contamination, spoilage-associated metabolites, and compositional or authenticity markers.

This category helps distinguish:

• Analyte-conversion enzymes from extraction enzymes, polymerases, and immunoassay reporters.
• Quantitative composition testing from pathogen, allergen, adulteration, or spoilage screening.
• Matrix challenges caused by fat, protein, pigments, preservatives, acidity, heat treatment, and processing.

A companion diagnostic is linked to the safe and effective use of a corresponding therapeutic product. Depending on the biomarker and platform, enzymes may support nucleic acid extraction, reverse transcription, PCR, isothermal amplification, sequencing-library preparation, target detection, or immunoassay signal generation. An enzyme becomes part of a CDx system only through development and validation within the specific test and therapeutic context.

CDx enzyme selection may emphasize:

• Analytical sensitivity, specificity, inhibitor tolerance, multiplex compatibility, and low background.
• Lot control, stability, manufacturability, documentation, and change-management needs.
• Co-development requirements connecting biomarker biology, specimen pathway, assay platform, and therapeutic program.

Molecular infectious disease assays detect pathogen-associated nucleic acid rather than relying on culture or an enzyme biomarker alone. DNA polymerases, reverse transcriptases, RNase inhibitors, ligases, helicases, strand-displacing polymerases, uracil-DNA glycosylase, and CRISPR-associated enzymes can perform amplification, carryover control, library construction, or sequence-specific detection.

Products may support:

• PCR, RT-PCR, qPCR, digital PCR, LAMP, RT-LAMP, and other validated amplification formats.
• DNA- and RNA-target workflows, multiplex panels, internal controls, and contamination-control strategies.
• Optimization for specimen-derived inhibitors, low-copy targets, reaction speed, and dry-reagent stability.

Oncology and genetic testing may interrogate sequence variants, copy-number changes, fusions, gene expression, methylation, or other molecular features. Polymerases, reverse transcriptases, ligases, nucleases, DNA-modifying enzymes, and sequencing-library preparation enzymes can support the workflow from extracted nucleic acid to an interpretable signal. Tumor profiling and inherited-variant testing differ in specimen, allele fraction, controls, and interpretation.

Selection should reflect:

• DNA or RNA input, FFPE tissue, liquid-biopsy material, germline specimens, or another defined sample type.
• Required limit of detection, variant class, multiplex level, library architecture, and sequencing or amplification platform.
• Fidelity, processivity, inhibitor tolerance, end-repair or ligation behavior, bias, background, and contamination control.

Some projects do not fit a single standard application category. Enzymes may be required for veterinary diagnostics, research-use assay prototypes, educational biochemical systems, industrial quality control, custom substrate conversion, or emerging analytical platforms. This section provides an entry point for products with cross-category or specialized uses.

For an uncommon application, define:

• The target, sample matrix, enzyme function, detection principle, and required controls.
• Whether an existing enzyme, modified variant, custom preparation, or complete development project is needed.
• Required scale, formulation, storage, analytical performance, and supporting documentation.